Production (Stage)
Kairos Pharma, Ltd.
KAPA
$0.4733
$0.00030.06%
AMEX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -39.32% | 245.26% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -12.45% | 277.55% | |||
| Operating Income | 12.45% | -277.55% | |||
| Income Before Tax | -28.78% | 6.40% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -28.78% | 6.40% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -28.78% | 6.40% | |||
| EBIT | 12.45% | -277.55% | |||
| EBITDA | 12.80% | -309.91% | |||
| EPS Basic | -8.61% | 23.75% | |||
| Normalized Basic EPS | 32.56% | -22.83% | |||
| EPS Diluted | -8.61% | 23.75% | |||
| Normalized Diluted EPS | 32.56% | -22.83% | |||
| Average Basic Shares Outstanding | 18.59% | 22.70% | |||
| Average Diluted Shares Outstanding | 18.59% | 22.70% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||